company background image
3347 logo

Hangzhou Tigermed Consulting SEHK:3347 Stock Report

Last Price

HK$32.20

Market Cap

HK$50.5b

7D

-2.0%

1Y

-1.5%

Updated

23 Dec, 2024

Data

Company Financials +

Hangzhou Tigermed Consulting Co., Ltd

SEHK:3347 Stock Report

Market Cap: HK$50.5b

My Notes

Capture your thoughts, links and company narrative

Hangzhou Tigermed Consulting Co., Ltd Competitors

Price History & Performance

Summary of share price highs, lows and changes for Hangzhou Tigermed Consulting
Historical stock prices
Current Share PriceCN¥32.20
52 Week HighCN¥58.80
52 Week LowCN¥22.10
Beta0.86
1 Month Change-0.46%
3 Month Change16.25%
1 Year Change-1.53%
3 Year Change-66.25%
5 Year Changen/a
Change since IPO-71.58%

Recent News & Updates

Recent updates

Shareholder Returns

3347HK Life SciencesHK Market
7D-2.0%1.6%-0.5%
1Y-1.5%-32.2%19.9%

Return vs Industry: 3347 exceeded the Hong Kong Life Sciences industry which returned -32.2% over the past year.

Return vs Market: 3347 underperformed the Hong Kong Market which returned 19.9% over the past year.

Price Volatility

Is 3347's price volatile compared to industry and market?
3347 volatility
3347 Average Weekly Movement15.8%
Life Sciences Industry Average Movement12.1%
Market Average Movement8.8%
10% most volatile stocks in HK Market18.6%
10% least volatile stocks in HK Market4.1%

Stable Share Price: 3347's share price has been volatile over the past 3 months compared to the Hong Kong market.

Volatility Over Time: 3347's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.

About the Company

FoundedEmployeesCEOWebsite
20049,348Xiaochun Caowww.tigermedgrp.com

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services.

Hangzhou Tigermed Consulting Co., Ltd Fundamentals Summary

How do Hangzhou Tigermed Consulting's earnings and revenue compare to its market cap?
3347 fundamental statistics
Market capHK$50.45b
Earnings (TTM)HK$1.02b
Revenue (TTM)HK$7.24b

53.2x

P/E Ratio

7.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
3347 income statement (TTM)
RevenueCN¥6.80b
Cost of RevenueCN¥4.27b
Gross ProfitCN¥2.54b
Other ExpensesCN¥1.58b
EarningsCN¥958.67m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)1.11
Gross Margin37.29%
Net Profit Margin14.10%
Debt/Equity Ratio15.2%

How did 3347 perform over the long term?

See historical performance and comparison

Dividends

1.0%

Current Dividend Yield

51%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 03:13
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hangzhou Tigermed Consulting Co., Ltd is covered by 39 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yang LuoBOCI Research Ltd.
Linda LuBOCI Research Ltd.
Bo LiBofA Global Research